oritavancin vs warfarin
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of oritavancin and warfarin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
A drug-drug interaction study that assessed the interaction potential of a single 1,200 mg dose of oritavancin on the pharmacokinetics of S-warfarin (CYP2C9 probe substrate) showed no effect of oritavancin on S-warfarin C max or AUC. Patients should be closely monitored for signs of toxicity or lack of efficacy if they have been given KIMYRSA while on a potentially affected compound (e.g., patients should be monitored for bleeding if concomitantly receiving KIMYRSA and warfarin).
Orbactiv
Coumadin, Jantoven
KIMYRSA is an antibiotic medicine. It is used to treat serious skin infections caused by certain bacteria.
Warfarin is a medicine that helps prevent blood clots. It is used to treat and prevent dangerous clots from forming in your body.
KIMYRSA treats acute bacterial skin and skin structure infections (ABSSSI) in adults. These infections are caused by specific Gram-positive bacteria. KIMYRSA can fight Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, among others. Your doctor will determine if KIMYRSA is the right medicine for your infection.
Warfarin is used to prevent and treat blood clots in your veins and lungs. It can also prevent clots if you have atrial fibrillation (irregular heartbeat) or a replacement heart valve. After a heart attack, it can lower the risk of death, another heart attack, or a stroke.
KIMYRSA is a lipoglycopeptide antibiotic. It works by stopping bacteria from building their cell walls. This kills the bacteria and helps to clear the infection.
Warfarin works by blocking your body's use of vitamin K. Vitamin K is needed to make blood clotting factors. By blocking vitamin K, warfarin makes your blood less likely to clot.
- • Headache
- • Nausea
- • Vomiting
- • Abscesses on limbs or under the skin
- • Diarrhea
- • Bleeding from any tissue or organ
- Pruritus 162
- Urticaria 105
- Rash 84
- Chills 83
- Back Pain 81
- International Normalised Ratio Increased 10,276
- Dyspnoea 8,408
- Drug Interaction 6,288
- Fatigue 6,143
- Nausea 5,921
You should not take KIMYRSA if you are using intravenous heparin. Do not use heparin for 5 days (120 hours) after getting KIMYRSA. Serious allergic reactions, including anaphylaxis, have been reported. Tell your doctor right away if you have signs of an allergic reaction.
Warfarin can cause major or fatal bleeding. You must have your blood tested regularly (INR) while taking warfarin. Many things, like other medicines and diet changes, can affect your INR. Tell your doctor about any bleeding and follow their instructions to prevent bleeding.
It is not known if KIMYRSA can harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if KIMYRSA passes into breast milk. Talk to your doctor about the best way to feed your baby if you take KIMYRSA.
Warfarin can harm your unborn baby, especially during the first three months of pregnancy. Do not take warfarin if you are pregnant, unless you have a mechanical heart valve and your doctor says the benefits outweigh the risks. Talk to your doctor if you are breastfeeding, and watch your baby for bruising or bleeding.
Also Compare, Nearby Drugs
Compare oritavancin with
How to Read This oritavancin vs warfarin Comparison
oritavancin is classified in the Lipoglycopeptide Antibiotic drug class, while warfarin sits within the Vitamin K Antagonist (Anticoagulant) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, oritavancin has 515 submissions while warfarin has 37,036. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to even though oritavancin does not change the amount of warfarin in your blood, taking them together might still increase the risk of side effects.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for oritavancin or warfarin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.